The market remained flat over the last week, but it is up 18% over the past year, with earnings forecast to grow by 17% annually. For those interested in smaller or newer companies, penny stocks—despite their somewhat outdated name—can still offer surprising value. When these stocks are backed by strong financial health and solid fundamentals, they can present unique opportunities for growth at lower price points.

Underneath we present a selection of stocks filtered out by our screen.

SNDL (SNDL)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: SNDL Inc. is involved in the production, distribution, and sale of cannabis products for the adult-use market both in Canada and internationally, with a market cap of $338.18 million.

Operations: The company generates revenue from three main segments: Liquor Retail at CA$527.02 million, Cannabis Retail at CA$328.85 million, and Cannabis Operations at CA$136.17 million.

Market Cap: $338.18M

SNDL Inc., with a market cap of $338.18 million, has diversified revenue streams from liquor retail (CA$527.02M), cannabis retail (CA$328.85M), and cannabis operations (CA$136.17M). Despite being unprofitable, SNDL's short-term assets exceed its liabilities, and it remains debt-free with a stable cash runway exceeding three years due to positive free cash flow growth. Recent strategic moves include share buybacks totaling CA$32.73 million and plans for acquisitions in the U.S., particularly in Florida and Texas, aiming to enhance processing capabilities amidst ongoing net losses reported for Q2 2026.

Treace Medical Concepts (TMCI)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Treace Medical Concepts, Inc. is a medical technology company that designs, manufactures, and markets medical devices in the United States, with a market cap of $284.20 million.

Operations: The company generates $205.31 million in revenue from its operations focused on the design, manufacture, and marketing of medical devices.

Market Cap: $284.2M

Treace Medical Concepts, Inc. has a market cap of US$284.20 million and generates US$205.31 million in revenue, yet remains unprofitable with increasing losses over the past five years at 19.2% annually. Despite raising its 2026 revenue guidance to US$204-212 million, it reported a net loss of US$15.87 million for Q2 2026 and continues to face high volatility in share price movements. The company has sufficient cash runway for over a year but struggles with increased debt levels from 28.7% to 87.9% over five years while maintaining experienced management and board teams amidst recent index reclassifications.

loanDepot (LDI)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: loanDepot, Inc. operates in the United States by originating, financing, selling, and servicing residential mortgage loans with a market cap of approximately $301.30 million.

Operations: The company's revenue is primarily derived from the originating, financing, and selling of mortgage loans, totaling $1.26 billion.

Market Cap: $301.3M

loanDepot, Inc., with a market cap of US$301.30 million and US$1.26 billion in revenue, faces challenges typical of penny stocks, including unprofitability and a high net debt to equity ratio of 1685%. Despite having sufficient cash runway for over three years if free cash flow grows at historical rates, the company is under pressure from an NYSE compliance notice due to its share price falling below $1.00. Recent investor activism highlights concerns about strategic direction and leadership effectiveness as loanDepot explores expanding its corporate presence with a new Miami center opening soon.

Make It Happen

• Explore the 311 names from our US Penny Stocks screener here.
• Contemplating Other Strategies? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.